Pallavi Barman

8PUBLICATIONS
14CO-AUTHORS
Cancer cell biologyNatural products and bioactive compoundsBiologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 27, 2026
Stimuli-responsive fluorogenic prodrugs of potent inhibitors targeting overexpressed metabolic enzymes in cancer.

|Feb 28, 2025
Synthetic organic polysulfanes as H<sub>2</sub>S donors and anticancer agents.

Abu Sufian, Debojit Bhattacherjee, Pallavi Barman

|Jul 31, 2024
Synthetic Benzylic Diselenides and Disulfides: Potential Anticancer Activities via Modulation of the ROS-Dependent Akt/β-Catenin Signaling Pathway.

Pallavi Barman, Roopjyoti Misra, Nikita Pal

|Apr 11, 2024
Inflammatory-stimuli-responsive turn-on NIR fluorogenic theranostic prodrug: adjuvant delivery of diclofenac and hydrogen sulfide attenuates acute inflammatory disorders.

Abu Sufian, Nidhi Parihar, Md Badirujjaman

|Sep 04, 2023
Dual-Stimuli-Activatable Hybrid Prodrug for the Self-Immolative Delivery of an Anticancer Agent and Hydrogen Sulfide with Turn-On Fluorescence.

Abu Sufian, Md Badirujjaman, Pallavi Barman

|Mar 31, 2023
Cysteine-responsive prodrug of the anti-cancer drug amonafide: fluorogenic adjuvant drug delivery with hydrogen sulfide (H<sub>2</sub>S).

Sulendar K Mahato, Pallavi Barman, Md Badirujjaman

Pageof 2

Frequent Collaborators

8 joint publications

Krishna P Bhabak

3 joint publications

Debojit Bhattacherjee

3 joint publications

Md Badirujjaman

3 joint publications

Rahul Kesarwani